# Burning Rock Biotech Ltd: overview BNR · Nasdaq · CIK 1792267 · [Healthcare](/sectors/healthcare.md) Pages: [Overview](/companies/bnr.md) · [Financials](/companies/bnr/financials.md) · [Filings](/companies/bnr/filings.md) · [Insiders](/companies/bnr/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [79.7](/filings/0001193125-22-133522.md) | [81.7](/filings/0001193125-23-108289.md) | [75.7](/filings/0001193125-24-119655.md) | [70.7](/filings/0001193125-25-101753.md) | [77.2](/filings/0001193125-26-183377.md) | | Gross margin | % | [71.7%](/filings/0001193125-22-133522.md) | [67.5%](/filings/0001193125-23-108289.md) | [67.6%](/filings/0001193125-24-119655.md) | [70.3%](/filings/0001193125-25-101753.md) | [74.7%](/filings/0001193125-26-183377.md) | | Operating margin | % | [(156.9%)](/filings/0001193125-22-133522.md) | [(174.1%)](/filings/0001193125-23-108289.md) | [(124.5%)](/filings/0001193125-24-119655.md) | [(69.3%)](/filings/0001193125-25-101753.md) | [(10.2%)](/filings/0001193125-26-183377.md) | | Net margin | % | [(156.9%)](/filings/0001193125-22-133522.md) | [(172.4%)](/filings/0001193125-23-108289.md) | [(121.6%)](/filings/0001193125-24-119655.md) | [(67.2%)](/filings/0001193125-25-101753.md) | [(10.3%)](/filings/0001193125-26-183377.md) | | Diluted EPS | $ per share | [0.00](/filings/0001193125-22-133522.md) | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(107)](/filings/0001193125-22-133522.md) | [(75.2)](/filings/0001193125-23-108289.md) | [(37.2)](/filings/0001193125-24-119655.md) | [(13.4)](/filings/0001193125-25-101753.md) | [(4.8)](/filings/0001193125-26-183377.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bnr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Kynam Capital Management, LP](/funds/1907884.md) | 2026-06-30 | $10.5m | 1,238,563 | | Added +11,008 | | [CRCM LP](/funds/1483234.md) | 2026-06-30 | $1.8m | 211,997 | | Reduced −70,100 | | [CRCM LP](/funds/1483234.md) | 2026-06-30 | $1.8m | 211,997 | | Reduced −70,100 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $442.3k | 52,838 | | Added +17,431 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $364.9k | 43,594 | | Added +28,322 | | [Amova Asset Management Americas, Inc.](/funds/1480751.md) | 2026-06-30 | $257.7k | 29,724 | | Reduced −413 | | [Sumitomo Mitsui Trust Group, Inc.](/funds/1475365.md) | 2026-06-30 | $248.8k | 29,724 | | Reduced −413 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $244.1k | 29,164 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $236.6k | 27,288 | | Added +9,619 | | [HSG Holding Ltd](/funds/1470766.md) | 2026-06-30 | $177.5k | 21,212 | | Unchanged | ## Recent filings [All 166 filings](/companies/bnr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-10 | 07:01 ET | [6-K](/filings/0001193125-26-387190.md) | Report of a foreign private issuer, period 2026-09-10 | 0001193125-26-387190 | | 2026-06-09 | 06:04 ET | [6-K](/filings/0001193125-26-262871.md) | Report of a foreign private issuer, period 2026-06-09 | 0001193125-26-262871 | | 2026-04-28 | 06:08 ET | [20-F](/filings/0001193125-26-183377.md) | Annual report of a foreign private issuer, period 2025-12-31 | 0001193125-26-183377 | | 2026-03-13 | 20:58 ET | [6-K](/filings/0001193125-26-104743.md) | Report of a foreign private issuer, period 2026-03-12 | 0001193125-26-104743 | | 2025-12-23 | 06:11 ET | [6-K](/filings/0001193125-25-329450.md) | Report of a foreign private issuer, period 2025-12-23 | 0001193125-25-329450 | | 2025-12-01 | 09:56 ET | [6-K](/filings/0001193125-25-303306.md) | Report of a foreign private issuer, period 2025-12-01 | 0001193125-25-303306 | | 2025-11-20 | 06:05 ET | [6-K](/filings/0001193125-25-288773.md) | Report of a foreign private issuer, period 2025-11-20 | 0001193125-25-288773 | | 2025-09-08 | 06:06 ET | [6-K](/filings/0001193125-25-197601.md) | Report of a foreign private issuer, period 2025-09-08 | 0001193125-25-197601 | | 2025-06-06 | 06:07 ET | [6-K](/filings/0001193125-25-136266.md) | Report of a foreign private issuer, period 2025-06-06 | 0001193125-25-136266 | | 2025-04-29 | 06:31 ET | [20-F](/filings/0001193125-25-101753.md) | Annual report of a foreign private issuer, period 2024-12-31 | 0001193125-25-101753 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-183377.md), filed Apr 28, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1792267 - Tickers: BNR - Exchange: Nasdaq - SIC code: 8071 Services-Medical Laboratories - State of incorporation: not reported - Filer category: Non-accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.